About Merlin
Merlin (NF2) is a protein
from Homo sapiens identified by UniProt accession
P35240, 595 residues long.
MolForge cross-references it against 0 known binders and
602 disease associations.
Target properties
| Protein name | Merlin |
| UniProt accession | P35240 |
| Gene | NF2 |
| Organism | Homo sapiens |
| Length | 595 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (602)
Diseases linked to this target (Open Targets).
- neurofibromatosis type 2 · score 0.84
- schwannoma · score 0.73
- schwannomatosis · score 0.69
- Pleural Mesothelioma · score 0.61
- familial meningioma · score 0.58
- hereditary neoplastic syndrome · score 0.57
- Inherited cancer-predisposing syndrome · score 0.56
- meningioma · score 0.55
- Vestibular schwannoma · score 0.54
- Malignant Mesothelioma · score 0.47
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P35240-F1 | alphafold | PREDICTED | 87.38 | — |
Amino-acid sequence (595 residues)
MAGAIASRMS FSSLKRKQPK TFTVRIVTMD AEMEFNCEMK WKGKDLFDLV CRTLGLRETW FFGLQYTIKD TVAWLKMDKK VLDHDVSKEE PVTFHFLAKF YPENAEEELV QEITQHLFFL QVKKQILDEK IYCPPEASVL LASYAVQAKY GDYDPSVHKR GFLAQEELLP KRVINLYQMT PEMWEERITA WYAEHRGRAR DEAEMEYLKI AQDLEMYGVN YFAIRNKKGT ELLLGVDALG LHIYDPENRL TPKISFPWNE IRNISYSDKE FTIKPLDKKI DVFKFNSSKL RVNKLILQLC IGNHDLFMRR RKADSLEVQQ MKAQAREEKA RKQMERQRLA REKQMREEAE RTRDELERRL LQMKEEATMA NEALMRSEET ADLLAEKAQI TEEEAKLLAQ KAAEAEQEMQ RIKATAIRTE EEKRLMEQKV LEAEVLALKM AEESERRAKE ADQLKQDLQE AREAERRAKQ KLLEIATKPT YPPMNPIPAP LPPDIPSFNL IGDSLSFDFK DTDMKRLSME IEKEKVEYME KSKHLQEQLN ELKTEIEALK LKERETALDI LHNENSDRGG SSKHNTIKKL TLQSAKSRVA FFEEL
Explore Merlin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets